secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001384101-26-000012
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte appoints Kevin Haas as Chief Development & Technology Officer, effective March 24, 2026
--------------------------------------------------------------------------------

- Dr. Kevin Haas, formerly CTO of Myriad Genetics (NASDAQ: MYGN), joins as Chief Development and Technology Officer.
- Compensation includes $500,000 base salary, 55% target bonus, RSUs and PSUs each valued at $1.5 million.
- RSU vests over four years; PSU vests upon achievement of performance objectives set by Compensation Committee.
- No family relationships or material transactions with the company or its other officers disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410126000012/0001384101-26-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410126000012/vcyt-20260313.htm
  HTML page:      https://secwatch.observer/filing/0001384101-26-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer